1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

Yet Another UK Call For Views On What Brexit Means For Pharma, Regulation & Health

 
• By Ian Schofield

Another inquiry investigation into the consequences of Brexit in the life sciences area has been launched, this time by the UK House of Commons health committee. Stakeholders are asked to comment on issues like the impact on the regulation of medicines and medical devices, how to ensure continued access to medicines, and whether transitional arrangements will be needed.

Archery
Another UK committee has the regulatory impact of Brexit in its sights

Is another investigation needed into the likely implications of Brexit for pharma firms, regulators and healthcare systems? Apparently so: the UK House of Commons Select Committee on Health has just launched an inquiry into the regulatory arrangements that will be needed post-Brexit to guarantee the supply of medicines and medical devices.

The committee says that with the UK preparing to withdraw from the EU and the European Atomic Energy Community (Euratom),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe

Infographic: Leqembi – A Geographical Comparison

 
• By Anabel Costa-Ferreira

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 
• By Eliza Slawther

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 
• By Francesca Bruce

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.